trial

Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

NCTId NCT00231335
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 30 (estimated)
Sponsored by Emory University
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-03
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
escitalopram

Sponsors

Emory UniversityLead Sponsor
Forest LaboratoriesCollaborator

Investigators

1
Dragan Bugarski-Kirola, MDPrincipal Investigator

Sites

0 total

Facts & assertions

3 sourced
Enrollment
30
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
escitalopram
drug
lead_sponsor
Emory University
company
collaborator
Forest Laboratories
company
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Dragan Bugarski-Kirola, MD
person